577 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
21 Recruiting Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Conditions: Gastrointestinal Tumors;   Pancreatic Tumors;   Gastrointestinal Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: Everolimus
22 Recruiting A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Liver Metastases
Intervention: Drug: 177Lu-DOTA-TATE
23 Unknown  Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors
Condition: Neuroendocrine Tumor
Intervention: Procedure: PET scan with Ga68-DOTANOC
24 Recruiting Best Therapy for Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention:
25 Unknown  ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention:
26 Recruiting 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'
Condition: Neuroendocrine Tumors
Intervention:
27 Recruiting Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Hepatic Metastases;   Metastases
Interventions: Drug: Everolimus;   Device: embolization;   Drug: Doxorubicin
28 Recruiting Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Condition: Neuroendocrine Tumor
Intervention: Other: Videoconsultation
29 Recruiting 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Condition: Neuroendocrine Tumours
Intervention: Drug: Diagnostic work up
30 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
31 Recruiting Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
Conditions: Liver;   Metastasis;   Neuroendocrine Tumors
Interventions: Radiation: 177Lutetium;   Procedure: Liver transplantation
32 Recruiting Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors
Conditions: Adult Medulloblastoma;   Childhood Medulloblastoma;   Neuroblastoma;   Neuroendocrine Tumor;   Somatostatinoma
Interventions: Radiation: gallium Ga 68-edotreotide;   Procedure: positron emission tomography/computed tomography;   Radiation: indium In 111 pentetreotide;   Procedure: computed tomography;   Procedure: contrast-enhanced magnetic resonance imaging
33 Recruiting Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Condition: NeuroEndocrine Tumours
Intervention: Drug: lanreotide acetate
34 Recruiting A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
Condition: Well-differentiated Neuroendocrine Tumors
Intervention: Drug: Metformin
35 Recruiting A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Intervention: Drug: Famitinib
36 Recruiting Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test);   Drug: Indium-111-Octreoscan (standard test)
37 Recruiting A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: sunitinib
38 Recruiting A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Intervention: Drug: lanreotide
39 Unknown  123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
40 Not yet recruiting Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival
Condition: Pancreatic Neuroendocrine Tumor
Intervention: Procedure: pancreatectomy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years